Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | PAN-301-1 |
Synonyms | |
Therapy Description |
PAN-301-1 is a vaccine targeting the human aspartyl/aspartate beta-hydroxylase (HAAH/ASPH) that triggers immune activity against tumor cells overexpressing HAAH (Journal of Clinical Oncology 36, no. 15_suppl, PMID: 32811566). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PAN-301-1 | SNS-301|SNS301|SNS 301|PAN 301-1 | PAN-301-1 is a vaccine targeting the human aspartyl/aspartate beta-hydroxylase (HAAH/ASPH) that triggers immune activity against tumor cells overexpressing HAAH (Journal of Clinical Oncology 36, no. 15_suppl, PMID: 32811566). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03120832 | Phase I | PAN-301-1 | Phase 1 Trial of PAN-301-1 in Cancer Patients | Completed | USA | 0 |